Differential regulation of rat 5-HT2A and 5-HT2C receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
M KuoppamäkiE Syvälahti

Abstract

Interactions with 5-HT2A and 5-HT2C receptors may be important for the actions of atypical antipsychotic drugs, such as clozapine (CLOZ). In this study we characterized the interaction of chlorpromazine (CPZ) and three putative atypical antipsychotic drugs, risperidone (RIS), amperozide (AMP), and ORG 5222 (ORG) with the 5-HT2A and the 5-HT2C receptor. CLOZ was used as a reference agent. These agents had 5-HT2C receptor-binding affinities (Ki values) in the following rank order: ORG (0.9 nM) > CLOZ (13.2 nM) > or = CPZ (27.1 nM) > RIS (112 nM) > > AMP (2580 nM). RIS (1.9 nM) and AMP (75.6 nM) had clearly higher affinities for the 5-HT2A than the 5-HT2C receptor; otherwise the 5-HT2A and 5-HT2C receptor affinities were approximately the same. Phosphoinositide hydrolysis studies in the rat choroid plexus revealed that all these agents were 5-HT2C receptor antagonists, with an approximately similar rank order of potency compared to the 5-HT2C receptor-binding data. Quantitative receptor autoradiography was used to study the regulation of 5-HT2A and 5-HT2C receptors after chronic treatment (14 days, SC injections once a day) with CLOZ (25 mg/kg), CPZ (15 mg/kg), RIS (0.3 mg/kg), AMP (5 mg/kg), and ORG (0.1 mg/kg). In the doses used...Continue Reading

Citations

Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Patricia A BroderickYueping Zhou
Oct 6, 1997·Biological Psychiatry·E V Gurevich, J N Joyce
Oct 31, 1996·European Journal of Pharmacology·G WongE R Korpi
Mar 26, 2003·Life Sciences·Dirk Van OekelenJosée E Leysen
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·Vincenzo Di MatteoEnnio Esposito
Jun 17, 1999·Pharmacology, Biochemistry, and Behavior·J M ScalzittiJ G Hensler
Sep 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Patricia A BroderickYueping Zhou
Aug 21, 2003·Progress in Neurobiology·Mark J Millan
Mar 10, 2000·Journal of Chemical Neuroanatomy·D Vergé, A Calas
Nov 13, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M Catalano
Jan 8, 2016·Progress in Neuro-psychopharmacology & Biological Psychiatry·A ChagraouiM Bourin
Jul 6, 2010·Journal of Chemical Neuroanatomy·Karolina Rogozinska, Jolanta Skangiel-Kramska
Oct 31, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Yong Kee ChoiFrank I Tarazi
Dec 27, 2008·Pharmacology & Therapeutics·V J AloyoJ A Harvey
Dec 14, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Axel Becker, Gisela Grecksch
Jun 24, 2005·Pharmacology, Biochemistry, and Behavior·M M Doat-MeyerhoeferR A Rabin
Aug 1, 2014·Behavioural Brain Research·Davide Amato
Nov 21, 1998·The European Journal of Neuroscience·P O TremblayC Rouillard
Apr 12, 2001·Journal of Neurochemistry·A AnjiJ G Hensler
Jun 10, 2017·Synapse·Yong Kee ChoiFrank I Tarazi
Jun 24, 2018·Synapse·Yong Kee Choi, Frank I Tarazi
Feb 26, 2008·Psychopharmacology·Frank I TaraziMohammed Shahid
Oct 31, 2002·Human Psychopharmacology·Marie NaughtonBrian E. Leonard
Aug 9, 2020·Frontiers in Neuroscience·Georg A Petroianu, Dietrich E Lorke
Mar 2, 2021·Biological & Pharmaceutical Bulletin·Maho TsubotaAtsufumi Kawabata
Mar 18, 2021·Reviews in Medical Virology·Zongsong WuHans H Hirsch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here